The results of the Early Venous Reflux Ablation (EVRA) trial were presented last month in London (Gohel et al, 2018). The ​world of venous leg ulcer (VLU) management has finally gained significant Level 1 evidence with the potential to change future practice. EVRA’s primary outcome was to research the effects of venous intervention on ulcer healing. The main conclusions were that early venous ablation of superficial venous reflux resulted in faster healing of VLUs, increased time free from ulceration and significant cost savings. These are important outcomes for patients, healthcare professionals and commissioners.